617 related articles for article (PubMed ID: 20809896)
1. Open access high throughput drug discovery in the public domain: a Mount Everest in the making.
Roy A; McDonald PR; Sittampalam S; Chaguturu R
Curr Pharm Biotechnol; 2010 Nov; 11(7):764-78. PubMed ID: 20809896
[TBL] [Abstract][Full Text] [Related]
2. Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case.
Kogej T; Blomberg N; Greasley PJ; Mundt S; Vainio MJ; Schamberger J; Schmidt G; Hüser J
Drug Discov Today; 2013 Oct; 18(19-20):1014-24. PubMed ID: 23127858
[TBL] [Abstract][Full Text] [Related]
3. The University of Kansas High-Throughput Screening Laboratory. Part II: enabling collaborative drug-discovery partnerships through cutting-edge screening technology.
McDonald PR; Roy A; Chaguturu R
Future Med Chem; 2011 Jul; 3(9):1101-10. PubMed ID: 21806374
[TBL] [Abstract][Full Text] [Related]
4. The European Lead Factory: An updated HTS compound library for innovative drug discovery.
van Vlijmen H; Ortholand JY; Li VM; de Vlieger JSB
Drug Discov Today; 2021 Oct; 26(10):2406-2413. PubMed ID: 33892142
[TBL] [Abstract][Full Text] [Related]
5. Novel trends in high-throughput screening.
Mayr LM; Bojanic D
Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
[TBL] [Abstract][Full Text] [Related]
6. Collaborative pre-competitive preclinical drug discovery with academics and pharma/biotech partners at Sanford|Burnham: infrastructure, capabilities & operational models.
Chung TD
Comb Chem High Throughput Screen; 2014 Mar; 17(3):272-89. PubMed ID: 24409951
[TBL] [Abstract][Full Text] [Related]
7. The European Lead Factory: Results from a decade of collaborative, public-private, drug discovery programs.
van Vlijmen H; Pannifer AD; Cochrane P; Basting D; Li VM; Engkvist O; Ortholand JY; Wagener M; Duffy J; Finsinger D; Davis J; van Helden SP; de Vlieger JSB;
Drug Discov Today; 2024 Mar; 29(3):103886. PubMed ID: 38244673
[TBL] [Abstract][Full Text] [Related]
8. Benefits of Strategic Small-Scale Targeted Screening.
Sharlow ER
Assay Drug Dev Technol; 2016 Aug; 14(6):329-32. PubMed ID: 27341343
[TBL] [Abstract][Full Text] [Related]
9. Fragment-based approaches in drug discovery and chemical biology.
Scott DE; Coyne AG; Hudson SA; Abell C
Biochemistry; 2012 Jun; 51(25):4990-5003. PubMed ID: 22697260
[TBL] [Abstract][Full Text] [Related]
10. An Analysis of Different Components of a High-Throughput Screening Library.
Saha A; Varghese T; Liu A; Allen SJ; Mirzadegan T; Hack MD
J Chem Inf Model; 2018 Oct; 58(10):2057-2068. PubMed ID: 30204440
[TBL] [Abstract][Full Text] [Related]
11. Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads.
Bergsdorf C; Ottl J
Expert Opin Drug Discov; 2010 Nov; 5(11):1095-107. PubMed ID: 22827747
[TBL] [Abstract][Full Text] [Related]
12. Screening Library Design.
Ashenden SK
Methods Enzymol; 2018; 610():73-96. PubMed ID: 30390806
[TBL] [Abstract][Full Text] [Related]
13. Data-driven approaches used for compound library design, hit triage and bioactivity modeling in high-throughput screening.
Paricharak S; Méndez-Lucio O; Chavan Ravindranath A; Bender A; IJzerman AP; van Westen GJP
Brief Bioinform; 2018 Mar; 19(2):277-285. PubMed ID: 27789427
[TBL] [Abstract][Full Text] [Related]
14. Evaluating and evolving a screening library in academia: the St Jude approach.
Nishiguchi G; Das S; Ochoada J; Long H; Lee RE; Rankovic Z; Shelat AA
Drug Discov Today; 2021 Apr; 26(4):1060-1069. PubMed ID: 33453364
[TBL] [Abstract][Full Text] [Related]
15. Hit Discovery for Public Target Programs in the European Lead Factory: Experiences and Output from Assay Development and Ultra-High-Throughput Screening.
Honarnejad S; van Boeckel S; van den Hurk H; van Helden S
SLAS Discov; 2021 Feb; 26(2):192-204. PubMed ID: 32734803
[TBL] [Abstract][Full Text] [Related]
16. Plate-based diversity subset screening generation 2: an improved paradigm for high-throughput screening of large compound files.
Bell AS; Bradley J; Everett JR; Loesel J; McLoughlin D; Mills J; Peakman MC; Sharp RE; Williams C; Zhu H
Mol Divers; 2016 Nov; 20(4):789-803. PubMed ID: 27631533
[TBL] [Abstract][Full Text] [Related]
17. A Guide to Run Affinity Screens Using Differential Scanning Fluorimetry and Surface Plasmon Resonance Assays.
Bergsdorf C; Wright SK
Methods Enzymol; 2018; 610():135-165. PubMed ID: 30390797
[TBL] [Abstract][Full Text] [Related]
18. Improving lead generation success through integrated methods: transcending 'drug discovery by numbers'.
Campbell JB
IDrugs; 2010 Dec; 13(12):874-9. PubMed ID: 21154146
[TBL] [Abstract][Full Text] [Related]
19. Biophysics in drug discovery: impact, challenges and opportunities.
Renaud JP; Chung CW; Danielson UH; Egner U; Hennig M; Hubbard RE; Nar H
Nat Rev Drug Discov; 2016 Oct; 15(10):679-98. PubMed ID: 27516170
[TBL] [Abstract][Full Text] [Related]
20. The University of Kansas High-Throughput Screening laboratory. Part I: meeting drug-discovery needs in the heartland of America with entrepreneurial flair.
McDonald PR; Roy A; Chaguturu R
Future Med Chem; 2011 May; 3(7):789-95. PubMed ID: 21644824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
